(MENAFN- EIN Presswire) EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

What Is The Estimated Industry Size Of HPV Associated Disorders Market?
The market for HPV associated disorders has seen robust growth in recent times. It is projected to expand from $20.73 billion in 2024 to $22.13 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.8%. The significant growth witnessed in the past years is due to an increase in the number of HPV-associated disorders, heightened awareness regarding HPV and the disorders it can cause, advancements in diagnostic methodologies, government-led initiatives encouraging HPV vaccinations, and an increasing demand for early detection and vaccination.

There is a prediction for robust expansion in the HPV related disorders market in the coming years. The market is projected to escalate to ""$29.01 billion in 2029, with a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this growth in the forecast period include the green light for new HPV vaccines, amplified efforts by governmental and private bodies for prompt screening and vaccination, increasing occurrence of cervical cancer, augmented demand for non-invasive diagnostic exams, and the inclusion of HPV testing in regular healthcare services. The forecast period is also expected to witness certain trends like the emergence of next-generation HPV vaccines, the rise of point-of-care HPV testing, a shift towards molecular methods for HPV detection, personalized strategies for HPV treatment, and the incorporation of HPV testing in women's health services.

Download a free sample of the hpv associated disorders market report:

What Are The Major Factors Driving The HPV Associated Disorders Global Market Growth?
A rise in the occurrence of HPV-related instances is anticipated to boost the growth of the HPV-associated disorders market. Such disorders encompass benign verrucae vulgates, condylomas acuminata and malignancies of the cervix, vulva, anus, and penis as well as anogenital warts, recurrent respiratory papillomatosis, and anogenital and oropharyngeal cancers. There is a significant global incidence of HPV infection, predominantly among women. Cancer reported in January 2022 that approximately 14,100 women will be diagnosed with invasive cervical cancer in the United States, and 604,127 women globally were diagnosed with cervical cancer in 2020. Moreover, it was projected that in 2023, there would be about 4,310 fatalities due to cervical cancer in the US. Therefore, the escalating prevalence of HPV instances is expected to fuel the growth of the HPV-associated disorders market.

Who Are The Leading Companies In The HPV Associated Disorders Market?
Major players in the HPV Associated Disorders include:
. AstraZeneca plc
. F. Hoffmann-La Roche Ltd
. Biocon Ltd
. GlaxoSmithKline plc
. Merck & Co Inc.
. Pfizer Inc.
. Eli Lilly and Company
. Sanofi S. A.
. Novartis AG
. Bristol-Myers Squibb Company

What Are The Prominent Trends In The HPV Associated Disorders Market?
A significant trend emerging in the field of HPV-related disorders is targeted therapies. Leading market participants are focusing on designing and implementing therapies aimed at diseases associated with HPV, such as cervical and oropharyngeal cancers, among others. These targeted treatments include drugs that are designed to focus on the vascular endothelial growth factor protein and the tissue-factor (TF) protein found in cancer cells. For instance, in September 2023, the US biopharmaceutical company INOVIO Pharmaceuticals disclosed that the U.S. Food and Drug Administration (FDA) assigned their investigative product, INO-3107, a Breakthrough Therapy designation. This product aims to treat Recurrent Respiratory Papillomatosis (RRP). This designation speeds up the development and review periods for therapies targeted at severe illnesses, especially when preliminary results show a significant improvement over current treatment options. INO-3107 has successfully triggered enduring immune responses against HPV types 6 and 11 by activating both CD4+ and CD8+ T cells essential for targeting infected cells.

What Are The Primary Segments Covered In The Global HPV Associated Disorders Market Report?
The hpv associated disorders market covered in this report is segmented –
1) By Indication: Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Anal Intraepithelial Neoplasia (AIN), Anal Cancer, Genital Warts, Other Indications
2) By Therapy: Prevention, Treatment
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Cervical Intraepithelial Neoplasia (CIN): CIN 1, CIN 2, CIN 3
2) By Cervical Cancer: Squamous Cell Carcinoma, Adenocarcinoma
3) By Anal Intraepithelial Neoplasia (AIN): AIN 1, AIN 2, AIN 3
4) By Anal Cancer: Squamous Cell Carcinoma, Other Types
5) By Genital Warts: Condylomata Acuminata
6) By Other Indications: Oropharyngeal Cancer, Vulvar and Vaginal Cancers, Other HPV-Related Conditions

View the full hpv associated disorders market report:

Which Region Is Forecasted To Grow The Fastest In The HPV Associated Disorders Industry?
In 2024, North America led the market for HPV associated disorders and its growth is anticipated to continue. The market report covers regions including Asia-Pacific - projected to be the most rapidly growing region, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global HPV Associated Disorders Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025
/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025
/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025
/report/gastrointestinal-drug-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...
The Business Research Company -

Follow Us On:
. LinkedIn: "

MENAFN21112025003118003196ID1110377357